Topical Pancreatic Duct Lidocaine for Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Recruitment status was Recruiting
The purpose of this study is to determine if lidocaine is effective in reducing the incidence of post-ERCP pancreatitis.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
|Official Title:||A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis|
- The primary outcome of interest will be development of acute pancreatitis defined as new or worsening abdominal pain post-ERCP associated with an increase in serum amylase at least 3 times the upper limit of normal. [ Time Frame: 24-48 hours post-procedure ] [ Designated as safety issue: No ]
|Study Start Date:||March 2010|
|Estimated Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
Drug: Lidocaine Hydrochloride
1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
|Active Comparator: Normal Saline||
Drug: Normal Saline
1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is a common cause of morbidity for which there is no known pharmacologic prophylaxis. Post-ERCP pancreatitis is thought to be caused by several factors, including intraductal pressure, multiple duct injections with contrast, and neural arc reflexes. Lidocaine is a safe, inexpensive class IV antiarrhythmic that has topical anesthetic effects, inhibits trypsin activity, and may potentially prevent post-ERCP pancreatitis by injection directly into the pancreatic duct at the time of ERCP. Lidocaine has been shown to inhibit phospholipase A2, a key pancreatic enzyme, interrupt local arc reflexes to stop neuronal transmission, and to dampen GI tract mucosal reflexes to prevent high ductal pressure.
The key objective of this study is to determine if injection of lidocaine is beneficial in preventing post-ERCP pancreatitis. Subjects will be randomized to study group or control group in an equal ratio. The physicians performing the ERCP will be unaware of the treatment group to which patients have been assigned. Study arm will receive contrast agent Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) during ERCP. Control arm will receive contrast agent Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) during ERCP. Diatrizoate diluted with normal saline is the standard of care. Patients will be contacted 1 day and 1 week post-ERCP to assess for symptoms of pancreatitis.
|Contact: Abraham Mathew, M.D., M.S.||717-531-3834|
|Contact: Brooke B Ancrile, Ph.D.||717-531-0003 ext firstname.lastname@example.org|
|United States, Pennsylvania|
|Penn State College of Medicine, Penn State Milton S. Hershey Medical Center||Recruiting|
|Hershey, Pennsylvania, United States, 17033|
|Principal Investigator: Abraham Mathew, M.D., M.S.|
|Sub-Investigator: Brooke B Ancrile, Ph.D.|
|Sub-Investigator: Thomas McGarrity, M.D.|
|Sub-Investigator: Nakechand Pooran, M.D.|
|Sub-Investigator: Charles Dye, M.D.|
|Sub-Investigator: Matthew Moyer, M.D.|
|Sub-Investigator: Robert Evans, M.D.|
|Sub-Investigator: Guoxiang Shi, M.D.|
|Sub-Investigator: Patrick McDevitt, D.O.|
|Sub-Investigator: Matthew Nikoloff, M.D.|
|Sub-Investigator: Kaveh Sharzehi, M.D.|
|Sub-Investigator: Vishal Jain, M.D.|
|Principal Investigator:||Abraham Mathew, M.D., M.S.||Milton S. Hershey Medical Center|